Finanzen von Karyopharm Therapeutics Inc (KPTI)KPTIKaryopharm Therapeutics Inc

Evaluating the bottom line, Karyopharm Therapeutics Inc. maintains a gross margin of 96.75%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -67.38%, while the net margin is -200.48%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively KPTI converts its operational activities into shareholder value.

In the context of the broader market, KPTI competes directly with industry leaders such as BFRI and LPCN. With a market capitalization of $18.87M, it holds a leading position in the sector. When comparing efficiency, KPTI's gross margin of 96.75% stands against BFRI's 79.92% and LPCN's 100.00%. Such benchmarking helps identify whether Karyopharm Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Karyopharm reported total revenue of $33.4 million for Q2 2026, down from $37.9 million in Q2 2025, indicating challenges in revenue generation. The gross margin remains strong at 96.75%, but the net margin is heavily negative at -200.48%.